Facts and Figures eople

Transcription

1 Facts and Figures 2012 eople

2 The company The company Content 2 Sales in million The is an independent, owner-operated The company The at a glance highlights hameln rds 4 hameln pharma 5 hameln plus 6 company group that is internationally active. The companies belonging to the focus their business activities on services for the development and manufacturing of sterile pharmaceuticals as well as the marketing of predominantly parenteral drugs. Internationally recognised pharmaceutical companies belong to the company's customers and they rely on the know-how and experience of more than 600 employees worldwide outlook 7 The at a glance Focussing on people Name Founded 1950 Headquarter langes Feld Hameln, Germany Our employees have pledged themselves to the guiding principle of focussing on people. They research, develop, produce and serve, committed to relieving human suffering and pain. In their understanding of corporate responsibility values, they never lose sight of the requirements of others whether that be product users, customers or colleagues. Chief Executive Officer Christoph Kerstein Chief Financial Officer gert Diederich Fiscal year Internet Companies belonging to the hameln rds gmbh (DE) Service specialist in the healthcare industry Key company figures Organisation hameln rds a.s. (Slovakia) Service specialist in the healthcare industry hameln pharmaceuticals gmbh Specialist for the contract manufacture of parenteral drugs Chief Executive Officer: Christoph Kerstein Company sales (in 1,000) 70,696 72,495 84,535 EBITDA (in 1,000) 6,295 7,239 6,589 Investments (in 1,000) 2,153 2,397 4,256 Employees hameln pharma plus gmbh Specialist for marketing parenteral drugs. 2 3

3 2012 highlights hameln rds 2012 highlights hameln pharma Sales in million Sales in million hameln rds provides services in the healthcare industry. With some 170 employees worldwide, hameln rds advises and serves both national and international clients from the pharmaceutical, biotechnology and medical technology sectors at all stages in the process from drug selection to delivery. hameln rds provides an extensive range of services offering product development and laboratory services in accordance with GLP, clinical and biological trials, a comprehensive licensing service including maintenance of existing authorizations and the reliable supply of active ingredients and finished products. hameln pharma has been a contract manufacturer of sterile solutions for more than 60 years. Approximately 400 employees of hameln pharma manufacture liquid pharmaceutical products either aseptically or terminally sterilised and filled in ampoules or vials for both national and international pharma companies. On the basis of cgmp and FDA certification hameln pharma produces pharmaceuticals that can be distributed to all healthcare markets in the world Expanded development focus Increasing the efficiency in "packaging" division In May 2013, the hameln rds Research and Development Centre teamed up with its long-standing cooperation partner of the University of Bratislava to acquire a new lyophilliser. The device is used for freeze-drying small batches of mainly biotechnological active ingredients that perish too rapidly in their aqueous, galenic state. The lyophilliser will enable hameln rds to expand its current development focus on biotechnological active ingredients. Pharmaceutical drugs based on biotechnological-active ingredients have gradually increased in importance over the last few years and are increasingly replacing chemical-synthesised drugs. (see graph) Quantity of marketed molecules AM with chemicalsynthesised active ingredients AM with biotechnologicalmanufactured active ingredients Particularly in the last quarter of 2012, hameln pharma achieved a significant volume increase in the second production stage, packaging. In the last two quarters of 2012, hameln pharma recorded an average output of over 30 million per quarter. The reasons for this increase lie in diverse improvements to managing system loads more effectively and the installation of a fourth thermoforming line. hameln pharma hopes that this clear trend towards volume growth will continue into also saw the launch of two new facilities to consolidate the visual inspection unit: A particle testing system and a crack detection machine. As part of the necessary restructuring work involved, the visual inspection area has been separated from the area designated for labelling and packaging products. Packaging volumes (per quarter) million Stability study portfolio expanded Project launched to increase productivity To keep in line with the increasing requirements of international pharmaceutical authorities, hameln rds installed new climatic chambers at its plant in Modra in May The climatic chambers are used to conduct stability studies on pharmaceutical drugs that can now test temperatures and air humidity that were previously not possible at the : 25 degrees Celsius at 60 percent air humidity and 30 degrees Celsius at 75 percent air humidity. Stability studies can be conducted at hameln rds with the following temperatures and air humidity: Temperature Air humidity 5 C 25 C 60 % 30 C 65 % 40 C 75 % 25 C 60 % 30 C 75 % hameln pharma announced major plans for the 2012 fiscal year to significantly increase the sales volume in production. The "Know How!" project was launched in 2012 with the objectives of restructuring processes and structures to support a volume increase and also of preparing the company for midterm growth. The "Know How!" project is intended to transform hameln pharma from a "function-oriented" into a "processoriented" organisation where company productivity increases significantly by making selective machine investments while maintaining the same number of personnel. 4 5

4 2012 highlights hameln plus 2013 outlook Sales in million hameln rds 2013: Innovative ideas to promote growth hameln plus is a specialist in marketing high-quality injectables in ampoules and vials that are primarily used in hospitals. The hameln plus portfolio focuses on products for intensive medicine, anaesthesiology and concomitant therapy in oncology. Today, hameln plus products are marketed in more than 40 countries worldwide. Doctors, pharmacists and nursing staff rely on the hameln plus knowhow and years of experience in the field of injectables. hameln rds plans a significant increase in volume for the fiscal year This goal is only attainable if hameln rds suppliers ensure a constant and on-time delivery of products and if dossiers are sold as planned. hameln rds are pushing ahead with development projects as planned. Customer and in-house project developments (start per year) Amount Accumulated amount Gradual, consistent expansion of sales region hameln pharma 2013: Leveraging market potential by increasing production efficiency 2012 again saw hameln plus expand its sales network with exports to Thailand, Israel and Kenya. hameln plus decided to rollout its most popular products in these three "new" countries: Ketamine, GTN (nitro-glucose) and Oxytocin were supplied to Israel, Fentanyl to Thailand and Ondansetron to Kenya. Product rollout on "new" 2012 markets Israel Ketamine GTN (nitro-glucose) Oxytocin hameln pharma can expect high growth rates in 2013 thanks to the consistently strong market demand. For 2013, hameln pharma is planning a 17 percent increase in sales. The company has strategic plans to restructure the corporate organisation and expand its plant with a vial filling facility. Operating OPEX plans and a growth in batches of high-volume vial products are planned to increase production efficiency. Kenya Ondansetron Thailand Fentanyl German market: record sales of over EUR 10 million hameln plus 2013: Continued growth with modernised product portfolio In 2006, hameln plus started marketing products for intensive medicine and anaesthesiology on the German domestic market. Following business developments that were more successful than originally forecast over the last four years, hameln plus sales figures have exceeded the ten million Euro mark for the first time in The trigger for this exceptional growth on the hameln plus domestic market was the noticeable development of tried-and-tested hameln plus products as well as the rollout of six new products in just one and a half years. The company has succeeded in consolidating its excellent reputation with its customers in the clinical environment new products Piritramide Octreotide Remifentanil 2012 new products Levofloxacin Amiodarone Cisatracurium hameln plus is again expecting to record a positive sales growth for Further growth is forecast for all sales regions of hameln plus. To consolidate this growth strategy in the coming years, hameln plus will rollout two new products in 2013, dimenhydrinate and zoledronic acid to modernise its existing product portfolio. Growth in all regions (net sales in EUR million) Asia Europe MENA South America

5 gmbh Langes Feld Hameln, Germany